Hansoh Pharmaceutical Group Company Limited
翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

VOLUNTARY ANNOUNCEMENT

LICENSING AGREEMENT WITH SCYNEXIS

The board of directors (the "**Board**") of Hansoh Pharmaceutical Group Company Limited (the "**Company**" and together with its subsidiaries, the "**Group**") is pleased to announce that on February 11, 2021, Hansoh (Shanghai) Health Technology Co., Ltd. (翰森(上海)健康科技有限公司) and Jiangsu Hansoh Pharmaceutical Group Company Ltd. (江蘇豪森藥業集團有限公司) (collectively, the "**Licensees**"), each a wholly-owned subsidiary of the Company, have entered into an exclusive license and collaboration agreement (the "**Licensing Agreement**") with SCYNEXIS, Inc. (NASDAQ: SCYX) ("**SCYNEXIS**").

Pursuant to the Licensing Agreement, the Licensees will obtain an exclusive license from SCYNEXIS to research, develop and commercialize ibrexafungerp (the "**Product**") in the People's Republic of China (including Hong Kong, Macau and Taiwan) (the "**Territory**"). In consideration for the exclusive license, the Licensees agree to pay to SCYNEXIS an upfront payment of US$10 million plus potential milestone payments and royalties. Such milestone payments are subject to the achievement of relevant milestone events, such as the obtaining of product regulatory approvals within the Territory.

The Product is a first-in-class, novel triterpenoid antifungal agent with broad-spectrum activity providing the therapeutic advantages of both intravenous and oral formulations. Its mechanism of action is fungicidal against *candida* species, meaning it kills fungal cells, and is in late-stage development for multiple indications, including life-threatening fungal infections in hospitalized patients.

The Product is currently under U.S. regulatory review for the treatment of vaginal yeast infections, also known as vulvovaginal candidiasis ("**VVC**"). In December 2020, the United States Food and Drug Administration (U.S. FDA) accepted a new drug application ("**NDA**") for the Product and granted a Prescription Drug User Fee Act (PDUFA) action date of June 1, 2021. The NDA is supported by positive results from two Phase 3, randomized, double-blind, placebo-controlled, multi-center studies (VANISH-303 and VANISH-306), in which oral ibrexafungerp demonstrated statistically superior efficacy and a favorable tolerability profile in women with VVC. If approved, the Product could be the first new antifungal class in over 20 years, as well as the first and only non-azole treatment for vaginal yeast infections.

The Company is of the view that that the cooperation with SCYNEXIS will enrich the Group's pipelines in the anti-infective therapeutic area. Through such international cooperation, the Company looks forward to providing more original anti-infective drugs for patients in the People's Republic of China and improving their quality of life. Such cooperation also strengthens the Group's leading position in the anti-infective therapeutic area, as well as the global business expansion of the Group.

SCYNEXIS is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. To the best knowledge and belief of the Company, SCYNEXIS is independent of, and not connected with, the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"). The transactions contemplated under the Licensing Agreement do not constitute any notifiable transactions or connected transactions of the Company under the Listing Rules.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, February 17, 2021

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Miss Sun Yuan as executive directors, Ms. Ma Cuifang as non-executive director, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.